One could conclude that JeanMarie Guenot’s past achievements were simply rewards for the strength and vibrancy of her youth. Some people might be expecting her pedigree to nose-dive having spent more than two decades in the pharmaceutical and biotechnological industry on guenotllc.com. 20 years is not a small amount of time. However, this great woman is proving doubters wrong by outperforming even some younger folks working with her. Only people working closely with her will appreciate this point as they see her on a daily basis.
Jeanmarie Guenot and her team in Amphivena Therapeutics work with utmost urgency. Why would they not? Recent statistics about cancer is shocking. Base on studies and researches, it is estimated that about 19 million people will be cancer patients by the year 2024. She and her subordinates keep joining forces with multiple alliances with a view to amassing sufficient resources and know-how for the purpose of knocking out cancer once and for all.
JeanMarie Guenot’s Amphivena Therapeutics put in an investigational new drug application for AMV564 last year. The U.S. Food and Drug Administration (FDA) accepted it on 10th of August, 2016 after rigorous scrutiny. AMV564 has proven to be an effective treatment option for cancer cell with CD33. It is a bispecific antibody that harnesses human immunity in combating cancer cells with CD33. The expression CD33 refers to a transmembrane receptor found in many cases
The early days of Jeanmarie Guenot’s career can be traced to Atlas Venture where she managed the venture capital investments of the company. She later joined Hoffman LaRoache as a scientist in charge of preclinical research and development. Amphivena Therapeutics, her current employer, focuses on developing immunotherapies against cancer.
JeanMarie Guenot earned her PhD from the University of California, San Francisco and her MBA from the Wharton School at the University of Pennsylvania. She is an authority when it comes to therapies that address cases of neurology, autoimmune diseases, oncology, cardiovascular diseases and ophthalmic diseases.
Learn more about Jeanmarie Guenot: http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance